These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3085136)

  • 61. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.
    Kane JM; Rifkin A; Quitkin F; Nayak D; Saraf K; Ramos-Lorenzi JR; Klein DF; Sachar EJ
    Psychiatry Res; 1979 Dec; 1(3):341-8. PubMed ID: 233160
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.
    Marder SR; Wirshing WC; Van Putten T; Mintz J; McKenzie J; Johnston-Cronk K; Lebell M; Liberman RP
    Arch Gen Psychiatry; 1994 Apr; 51(4):280-7. PubMed ID: 8161288
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Very high dosage vs standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients.
    Quitkin F; Rifkin A; Klein DF
    Arch Gen Psychiatry; 1975 Oct; 32(10):1276-81. PubMed ID: 1101842
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
    Tune LE; Creese I; Coyle JT; Pearlson G; Snyder SH
    Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Depot fluphenazine decanoate and enanthate for schizophrenia.
    David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Plasma fluphenazine levels in patients receiving two doses of fluphenazine decanoate.
    Marder SR; Hubbard JW; Van Putten T; Hawes EM; McKay G; Mintz J; May PR; Midha KK
    Psychopharmacol Bull; 1986; 22(1):264-6. PubMed ID: 3726072
    [No Abstract]   [Full Text] [Related]  

  • 68. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
    Heresco-Levy U; Greenberg D; Lerer B; Javitt DC; Brown WA
    Isr J Psychiatry Relat Sci; 1997; 34(4):281-9. PubMed ID: 9409085
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High doses of fluphenazine enanthate in schizophrenia. A controlled study.
    Dencker SJ; Johansson R; Lundin L; Malm U
    Acta Psychiatr Scand; 1978 May; 57(5):405-14. PubMed ID: 354329
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia.
    Glazer WM
    Schizophr Res; 1988; 1(6):425-9. PubMed ID: 3154530
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.
    Viala A; Ba B; Durand A; Gouezo F; Hou N; Jørgensen A
    Psychopharmacology (Berl); 1988; 94(3):293-7. PubMed ID: 2895936
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
    Soni SD; Wiles D; Schiff AA; Bamrah JS
    Br J Psychiatry; 1988 Sep; 153():382-4. PubMed ID: 3250675
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
    Altamura AC; Mauri MC; Girardi T; Panetta B
    Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR; Levine J
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Fluphenazine decanoate dose and severity of depression in patients with post-psychotic depression.
    Siris SG; Strahan A; Mandeli J; Cooper TB; Casey E
    Schizophr Res; 1988; 1(1):31-5. PubMed ID: 3154504
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.
    Mandel MR; Severe JB; Schooler NR; Gelenberg AJ; Mieske M
    Arch Gen Psychiatry; 1982 Feb; 39(2):197-203. PubMed ID: 6121543
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
    Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W; Boisvert D; Bradwejn J
    Psychopharmacol Bull; 1984; 20(1):108-9. PubMed ID: 6371871
    [No Abstract]   [Full Text] [Related]  

  • 79. Fluphenazine decanoate and tardive dyskinesia: a possible association.
    Csernansky JG; Grabowski K; Cervantes J; Kaplan J; Yesavage JA
    Am J Psychiatry; 1981 Oct; 138(10):1362-5. PubMed ID: 7294195
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
    Carpenter WT; Buchanan RW; Kirkpatrick B; Lann HD; Breier AF; Summerfelt AT
    Am J Psychiatry; 1999 Mar; 156(3):412-8. PubMed ID: 10080557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.